France's Vetoquinol 2025 sales flat, profitability rises

Vetoquinol SA

27/03/2026 07:28

Overview

France animal health firm's 2025 sales flat at constant FX, down 2.5% as reported

Essential products grew 4.1% at constant FX, now 64% of total sales

Profitability improved as gross margin rose

Outlook

Company says 2026 began in a highly uncertain geopolitical and economic environment

Vetoquinol will continue geographic expansion of Essential products in 2026

Company says it will maintain responsive expense management in line with business trends

Result Drivers

ESSENTIALS GROWTH - Essentials product sales rose 4.1% at constant FX, now 64% of sales, supporting overall performance

PRODUCT MIX & PRICING - Improved gross margin attributed to higher Essentials share and increased selling prices, offsetting input cost inflation

COST CONTROL - Decrease in external expenses and stable personnel costs contributed to profitability

Company press release: ID:nBw8YpNQQa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
EUR 57 mln
FY EBIT
EUR 78.80 mln
FY EBITDA
EUR 113.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Vetoquinol SA is €89.00, about 10.7% above its March 26 closing price of €80.40

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)